ONC Insider Trades: ADS Sales Under 10b5-1 Plan and Option Holdings Disclosed
Rhea-AI Filing Summary
BeOne Medicines reporting person Henry Lee (SVP, General Counsel and Director) disclosed multiple ADS and option transactions on 08/13/2025. The filing shows several sales of American Depositary Shares under a Rule 10b5-1 plan adopted May 14, 2025, including disposals at weighted-average prices of $300 and $301.00 per ADS and a separate sale at $300.1858. The report also records acquisitions of ADS at prices of $194.47 and $159.03 and net changes in ordinary shares reflecting ADS conversions (1 ADS = 13 ordinary shares). Two option grants (or holdings) remain outstanding with exercise prices of $14.96 and $12.23 covering 56,953 and 50,037 ordinary shares respectively, and vesting schedules described in the filing.
Positive
- None.
Negative
- None.
Insights
TL;DR: Officer executed multiple ADS sales under a 10b5-1 plan while holding substantial exercisable options and some ADS purchases at lower prices.
The filing documents routine insider activity by an executive who is also a director. Material elements include multiple sales of American Depositary Shares executed pursuant to a Rule 10b5-1 plan adopted May 14, 2025, with weighted-average sale prices reported near $300 per ADS and one set near $301.00. The report also shows acquisitions of ADS at materially lower prices ($194.47 and $159.03), and outstanding stock option positions exercisable into 56,953 and 50,037 ordinary shares with exercise prices of $14.96 and $12.23 and multi-year vesting schedules. For investors, the filing documents changes in beneficial ownership and option exposure but contains no operational or financial results.
TL;DR: Disclosure aligns with standard Section 16 reporting; 10b5-1 plan sales are explicitly noted and vesting/accelerated vesting terms are provided.
The Form 4 clearly indicates the sales were effected under a documented Rule 10b5-1 trading plan (adopted May 14, 2025), which supports an affirmative defense for the reported sales. The filing includes explicit vesting schedules for two option grants and notes accelerated vesting upon certain termination events. Signatures and required explanatory footnotes (including weighted-average price disclosures and ADS-to-ordinary share conversion ratio of 1:13) are present. This is a governance-compliant disclosure of insider transactions rather than a corporate-change disclosure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) | 56,953 | $0.00 | -- |
| Exercise | Share Option (Right to Buy) | 50,037 | $0.00 | -- |
| Sale | American Depositary Shares | 1,112 | $300.00 | $334K |
| Exercise | American Depositary Shares | 4,381 | $194.47 | $852K |
| Exercise | American Depositary Shares | 3,849 | $159.03 | $612K |
| Sale | American Depositary Shares | 6,052 | $300.1858 | $1.82M |
| Sale | American Depositary Shares | 3,849 | $301.001 | $1.16M |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.00 to $300.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.00 to $301.03, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
